Articles tagged with Ovarian Cancer
Researchers found a potential therapeutic candidate, miR-506, which blocks epithelial-to-mesenchymal transition and inhibits mesenchymal markers in ovarian cancer cells. Higher miR-506 expression is associated with longer overall survival.
A phase II clinical trial shows that selumetinib, a targeted therapy, can halt growth or shrink tumors in 15% of patients with recurrent low-grade ovarian cancer. The two-year overall survival rate is 55%, and the median overall survival has not been reached due to high patient survival rates.
A two-step personalized immunotherapy treatment using dendritic cell vaccine and adoptive T cell therapy has triggered anti-tumor immune responses in patients with late-stage ovarian cancer. Four of six patients treated responded to the therapy, showing promising early results.
A preclinical study identifies Src, a master regulator of cancer cell proteins, as the key molecular switch affecting ovarian cancer progression. Beta blocker drugs mitigate this effect, reducing cancer deaths and mortality among patients with ovarian and cervical cancer.
A University of Central Florida professor has discovered a protein present in several types of cancer that could help prevent tumors from coming back. The protein, KLF8, appears to protect tumor cells from drugs and aid their regeneration.
Researchers develop SAPS algorithm to identify significant prognostic gene sets associated with patient survival, overcoming limitations of previous methods. The study found new prognostic signatures in breast and ovarian cancer subtypes, suggesting shared therapeutic targets and potential for improved diagnostics and treatments.
Researchers found that women with ovarian cancer had higher blood calcium levels than those without the disease. The study suggests that high calcium levels may be a biomarker for early detection of ovarian cancer.
Researchers at IDIBELL-Bellvitge Biomedical Research Institute have developed a new method to diagnose hereditary breast and ovarian cancer syndrome based on mass sequencing of BRCA1 and BRCA2 genes. The new protocol has been shown to be highly sensitive and specific, reducing costs and time for obtaining results.
Researchers created a genomic sequencing test, 'PapGene', using cervical fluid from routine Pap tests to detect ovarian and endometrial cancers with high accuracy. The test distinguished cancerous DNA from normal DNA, detecting both early and late-stage diseases.
Researchers at Yale School of Medicine have identified a key link between stem cell factors that fuel ovarian cancer's growth and patient prognosis. The study reveals a connection between Lin28 and BMP4, which has implications for developing novel targeted therapies.
Researchers found that Xbp1s regulates liver metabolic switch after eating, while low iron accelerates H. pylori-induced gastric cancer. Additionally, p62 is crucial for brown fat thermogenesis, and dendritic cells play a protective role in atherosclerosis.
Among eligible women, 19.1% underwent risk-reducing salpingo-oophorectomy (RRSO) and 39.6% used screening procedures, with women receiving a positive BRCA test result having increased odds of these interventions, while true-negative results were associated with reduced odds.
A nationwide survey of obstetricians and gynecologists found that many doctors perform routine pelvic exams in low-risk women due to misconceptions about ovarian cancer screening. The study suggests that the exams may be performed for non-clinical reasons, such as reassurance or expectation, rather than medical necessity.
Researchers found that ovarian cancer patients who took metformin lived significantly longer than those who did not, with a 3.7 times increased survival rate after accounting for other factors. The study suggests metformin may be considered for prevention or treatment of ovarian cancer.
A Mayo Clinic-led study found that patients with ovarian cancer who took metformin for their diabetes had a better survival rate than those who did not take the medication. After five years, 67% of metformin-takers were still alive compared to 47% of non-takers.
Researchers have found that dual-agent chemotherapy resistance in ovarian cancer arises from unique genetic changes, distinct from single-agent resistance. This discovery may lead to new strategies for overcoming resistance and improving treatment outcomes.
A study published in Cancer Discovery reveals that microRNAs can modify gene expression, converting normal fibroblasts into cancer-associated fibroblasts that promote tumor growth. The researchers identified three microRNAs involved in this process and found that inhibiting these signals could disrupt the cancer's support system.
Researchers have discovered a novel mechanism by which normal stromal cells around ovarian cancer cells are converted into cancer-promoting cells. Altering microRNA expression in these cells enhances tumor growth and metastasis, providing new potential therapeutic targets.
A UNM Cancer Center researcher is investigating the link between mitochondrial DNA and ovarian cancer. She hopes to identify genetic markers that could lead to a screening test or therapy, potentially increasing survival rates.
New research reveals that highly metastatic ovarian cancer cells are softer than less aggressive ones, suggesting cell stiffness as a valuable biomarker. This discovery could aid in the development of optimal chemotherapies for various types of cancer.
Women who regularly use aspirin have a decreased risk of serous ovarian cancer, an aggressive form of the disease. However, the benefit must be balanced against potential adverse effects of pain medication use.
Scientists at USC have discovered a new type of drug that works by targeting Protein Disulfide Isomerase (PDI) in ovarian cancer cells. The drug, PACMA31, has shown promise in reducing the number of doses needed and making it effective for patients with resistant cancer.
UNM Cancer Center researchers have identified R-ketorolac as a potential treatment for ovarian cancer cells, using flow cytometry and computer modeling to target specific GTPases. Initial animal studies show promising results in controlling tumor growth.
Researchers at Moffitt Cancer Center have discovered that microRNA miR-214 plays a critical role in regulating ovarian cancer stem cell properties. The study found that miR-214 induces the expression of a stem cell transcription factor (Nanog), leading to chemoresistance and potentially serving as a therapeutic target for ovarian cancer.
A Montreal-based research team has identified genetic patterns in ovarian cancer tumors that relate to patient survival after initial surgery. The study found that patients with mutant p53 protein had longer survival rates compared to those without.
A simple three-question paper-and-pencil survey can effectively identify women experiencing symptoms that may indicate ovarian cancer. The study involved 1,200 women and found that the screening tool identified 5% of women with a positive symptom score, resulting in one diagnosis of ovarian cancer.
The US Preventive Services Task Force recommends against annual screening for ovarian cancer in asymptomatic women due to potential harms. Reduced out-of-pocket expenses can improve medication adherence for chronic conditions, with case management and patient education showing strong evidence.
Researchers found that ovarian cancer cells hijack surrounding tissues by activating the HOXA9 gene, which induces TGF-β production and stimulates tumor growth. Blocking TGF-β expression reduced tumor growth, suggesting potential therapeutic targets for treating ovarian cancer.
MIT researchers have developed RNA-delivering nanoparticles that allow for rapid screening of new drug targets in mice. These nanoparticles target the ID4 protein, shrinking ovarian tumors in their first mouse study. The technology has the potential to relieve a significant bottleneck in cancer-drug development.
Lynn and Foster Friess are donating up to $100,000 to support ovarian cancer research at the Translational Genomics Research Institute. The challenge aims to advance cutting-edge genetic technology in pursuit of better cancer treatments.
A new study shows that ovarian grafts can maintain hormonal function for more than seven years in some women, providing a long-term solution for fertility preservation. This breakthrough could benefit young cancer survivors with premature ovarian failure, enabling them to retain reproductive health for an extended period.
A new study by UC Irvine finds significant racial and socioeconomic disparities in ovarian cancer care and survival rates. Poor women and those without insurance face significantly lower survival rates compared to their white and affluent counterparts.
A DNA repair pathway-focused score has been developed to predict chemotherapy response in ovarian cancer patients. The score is positively correlated with complete response rate, recurrence-free survival, and progression-free survival, and outperforms other clinical factors in predicting overall survival.
Scientists have identified bimodal genes acting as molecular switches in ovarian cancer, providing potential targets for clinical prognostic and diagnostic testing. These gene expressions are associated with different tumor subtypes and patient survival outcomes.
A genetic marker in blood can determine if a patient with ovarian cancer will benefit from chemotherapy after surgery. This discovery offers hope to patients diagnosed at stage III of the disease, who have a poor prognosis without effective treatment.
A study analyzing data from 47 studies found that increasing height increases the risk of ovarian cancer by 3% per decade. For body mass index, risks vary depending on whether women have taken menopausal hormone therapy, with an attenuated relationship in never-users.
A CCNY professor is evaluating MabCure Inc.'s monoclonal antibodies as a potential diagnostic reagent for ovarian cancer. The goal is to develop an early detection test that could improve the 94% five-year survival rate of the disease.
A large-scale study has identified hundreds of associations between mutations in cancer genes and sensitivity to anticancer drugs. The research may lead to more effective treatments for childhood bone cancer, such as Ewing's sarcoma, by targeting specific genetic markers.
Researchers discovered that reduced expression of OGFr accelerates tumorigenesis in human ovarian cancer. The OGF-OGFr axis plays a fundamental role in regulating cell proliferation.
Women with a history of endometriosis are at a significantly higher risk of developing three specific types of ovarian cancer. The study found that endometriosis is linked to a more than threefold chance of developing clear-cell ovarian cancers and over double the risk of developing endometrioid tumours.
A new model of aggressive ovarian cancer reveals that dendritic cells actively support tumor progression, but can be restored to suppress it. Researchers propose targeting dendritic cells to control metastatic ovarian cancer.
A study by Wayne State University School of Medicine researchers found that targeted tumor freezing therapy increases ovarian cancer survival rates, with a 56-month average survival rate reported in 98% of patients. The treatment, called cryoablation, has been shown to be cost-effective, saving an average of $26,806 per life year.
Researchers found a powerful cause-and-effect relationship between elevated platelets and ovarian cancer progression. Tumors stimulate platelet production, which strengthens the disease, reducing survival rates in patients with thrombocytosis.
The study aims to determine whether the MYC gene family is involved in the development and chemotherapy-resistance of high-grade serous ovarian cancers. Changes in MYC-family proteins have been identified as a potential cause of at least 15-20 per cent of these cancers, associated with poor clinical outcomes.
Scientists at Dana-Farber Cancer Institute have discovered a subtype of ovarian cancer that is susceptible to anti-angiogenic drugs, which block blood vessel formation. The subtype accounts for approximately one-third of all serous ovarian cancers and may benefit from therapies currently being tested in other cancers.
Researchers analyzed tumor specimens from 19 advanced stage carcinoma patients, discovering changes in biomarker expression that may impact therapy selection for women with recurrent ovarian cancer. The study highlights the importance of analyzing current tumor tissue to make informed treatment decisions.
The Australian Cancer Research Foundation has committed $2 million to two new cancer research laboratories at the Walter and Eliza Hall Institute. The new facilities will enable researchers to study the biology of epithelial cancers and develop new treatments for breast, ovarian, lung, and leukemia patients.
A study by researchers at H. Lee Moffitt Cancer Center and colleagues identified 27 genes involved in inflammation as related to ovarian cancer risk. The study found that variants in five of these genes, such as IL1A, were associated with lower ovarian cancer risk.
The American College of Physicians recommends metformin as the initial drug treatment for most patients with type 2 diabetes who have failed lifestyle modifications. Additionally, a study found that women are more likely to experience complications after implantable cardioverter-defibrillator (ICD) placement compared to men. Meanwhile,...
DIM inhibits ovarian cancer cell growth by blocking STAT3 activation and reducing IL-6 levels. The combination of DIM and cisplatin suppresses tumor growth in mice by an extra 50% compared to cisplatin alone.
A study found that women with invasive epithelial ovarian cancer and a BRCA gene mutation had improved 5-year overall survival, with BRCA2 carriers having the best prognosis. The study analyzed data from 26 observational studies and included 1,213 cases with pathogenic germline mutations in BRCA1 or BRCA2.
Researchers reassessed symptom indices to detect ovarian cancer early on, finding similar results to previous reports and a limited benefit in advancing diagnosis. The study highlights the challenges of detecting ovarian cancer early due to its biology, screening limitations, and clinical characteristics.
A study by OHSU Knight Cancer Institute suggests that faulty proteins may be key to identifying new treatments for ovarian cancer. Researchers found that 41% of patients with early disease recurrence had abnormal levels of other proteins, opening up a new direction in treatment.
Men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial had no evidence of a mortality benefit from annual PSA testing compared to usual care. The study found a higher percentage of deaths from other causes among prostate cancer patients diagnosed with PSA screening, indicating over-diagnosis.
A new phase 3 clinical trial shows that targeted therapy bevacizumab effectively delays the progression of advanced ovarian cancer. Patients with newly diagnosed advanced ovarian cancer can now benefit from an additional treatment option, alongside surgery and chemotherapy.
A clinical trial led by Drs. Amit Oza and Timothy Perren found that treating ovarian cancer with bevacizumab (
A research team led by Dr. David Huntsman and Dr. Gregg Morin found that mutations in the DICER gene were responsible for rare, unrelated cancers, revealing a fundamental process underlying these tumors. The discovery has the potential to lead to new approaches to treating both rare and common cancers.
A phase 2 study shows that aflibercept reduces the development of malignant ascites, a common complication of advanced ovarian cancer, and improves symptoms. However, it also increases the risk of fatal bowel perforations.
A new study found that women with BRCA1 or BRCA2 mutations inherited from their fathers tend to be diagnosed with breast cancer a decade earlier than those who inherit the genes from their mothers. The research analyzed 130 patients and discovered significant differences in age of diagnosis based on parent-of-origin effects.
Researchers identified a DNA methylation site that can detect ovarian cancer recurrence in blood samples, offering potential enhancement to existing biomarkers. This epigenetic marker may help monitor disease status after surgery and improve detection of the disease.